FY25 Revenue
₹408 Cr
+2.9% YoY · 8-yr CAGR 8.6%
FY25 EBITDA
₹79.1 Cr
19.4% margin · ↓0.7pp YoY
FY25 PAT
₹39.1 Cr
9.6% margin · ↓10.9% YoY
Peak EBITDA
₹107 Cr
FY23 · 25.6% margin
Margin Gap
-6.2pp
FY25 vs FY23 peak EBITDA%
ROE (FY25)
9.5%
Down from 16.3% at peak
🚨 Critical Finding: Revenue-Growth / Margin-Compression Trap
Revenue has nearly doubled from FY18 (₹228 Cr) to FY25 (₹408 Cr), but EBITDA margin peaked in FY23 at 25.6% and has compressed to 19.4% — a 6.2pp decline in just 2 years. Costs are growing faster than revenue. The hospital crossed ₹400 Cr revenue but is earning less profit than it did at ₹420 Cr (FY23). This is the classic "growth without profitability" pattern that requires immediate cost intervention.
Consolidated P&L — Full 8-Year Trend (₹ Lakhs)
All figures audited · YoY% and margin% in tooltips · CAGR in last column
Revenue & EBITDA Trajectory
Bar = Revenue · Line = EBITDA margin %
Profit Waterfall: Revenue → PAT (FY25)
How each cost layer eats into top-line
YoY Growth Rates — Revenue vs EBITDA vs PAT
Divergence between revenue growth and profit growth signals cost creep
Indexed Performance (FY18 = 100)
Revenue, EBITDA, PAT normalized to base year
FY25 Revenue
₹40,752 L
₹407.5 Cr
FY25 YoY Growth
+2.9%
₹1,130L incremental
FY18–FY25 CAGR
8.6%
₹228 Cr → ₹408 Cr
COVID Trough
FY21
₹242 Cr · ↓20.5%
Peak Revenue
FY23
₹419 Cr · Revenge spend
Other Income %
2.0%
₹823L FY25 (treasury)
Revenue Story in 3 Acts
Act 1 (FY18–FY20): Steady organic growth at 15.5% CAGR, maturing from ₹228 Cr to ₹305 Cr — strong ramp-up phase. Act 2 (FY21): COVID shock — revenue cratered 20.5% to ₹242 Cr. Act 3 (FY22–FY25): V-shaped recovery peaking at ₹419 Cr in FY23, but then revenue plateaued — FY24 was actually negative (–5.5%) and FY25 shows only +2.9%. The hospital is struggling to break through the ₹420 Cr ceiling.
Revenue Trend with Growth Phases
Bar = Revenue · Color = growth phase
Revenue vs Other Income Composition
Other income growing — treasury yield improving
Revenue Growth Bridge — Year-on-Year Incremental Revenue (₹ Lakhs)
Positive = growth year · Negative = contraction
Other Income Analysis
Rising from 1.1% of revenue in FY18 to 2.0% — mostly interest income on growing cash pile
Total Costs FY25
₹337 Cr
82.6% of revenue
Material Cost %
28.6%
₹117 Cr · Stable
People Cost %
36.7%
Payroll+Doctors ₹149 Cr
Mktg Cost % of Rev
1.7%
₹7 Cr · ↑49% YoY
🔍 Cost Structure Diagnosis
The "big 3" cost heads — Materials (28.6%), Payroll (19.5%), and Doctor Costs (17.2%) — together consume 65.3% of revenue. The critical shift: Doctor cost has dropped from 18.1% in FY23 to 17.2% in FY25 (positive), but Payroll has climbed from 15.2% to 19.5% (negative). Net-net, people costs are rising. Marketing spend has nearly 6x'd from FY18 but is still modest at 1.7% — suggesting the hospital may be under-investing in growth.
Cost Structure as % of Revenue — Stacked Area
Key buckets as percentage of revenue over time
FY25 Cost Breakdown (₹ Lakhs)
Where the money goes
Cost Head Trends — % of Revenue (The Margin Levers)
Each row shows how that cost head has moved as a share of revenue
Cost CAGR vs Revenue CAGR — Who's Running Faster?
Red bars = cost growing faster than revenue = margin drag · Green = lean cost head
EBITDA Margin
19.4%
FY25 · Peak 25.6% (FY23)
EBIT Margin
13.0%
FY25 · Peak 20.2% (FY23)
PBT Margin
12.9%
Finance cost now negligible
PAT Margin
9.6%
Peak 13.7% (FY23)
Eff. Tax Rate
25.8%
Normalized from 30.2% FY23
📐 Margin Architecture: The Compression Story
The hospital's margin expansion from FY18 (8.8%) to FY23 (25.6%) was one of the best in Indian hospitals — driven by post-COVID pent-up demand and operating leverage. But FY24–FY25 show a concerning reversal: EBITDA margin dropped 6.2pp. The silver lining: EBIT-to-PBT conversion is near-perfect at 99.4% (finance costs almost zero), meaning the margin compression is purely operational, not financial leverage.
Margin Cascade — EBITDA → EBIT → PBT → PAT (%)
All margins as % of revenue across years
Margin Spread: EBITDA vs PAT
Gap = depreciation + finance + tax burden
Margin Walk: FY23 (Peak) → FY25 — What Changed? (pp of Revenue)
Decomposing the 6.2pp EBITDA margin decline — positive = margin improvement, negative = margin drag
Depreciation & Finance Cost as % of Revenue
Below-EBITDA items — finance cost nearly eliminated
Effective Tax Rate Trend
Tax rate volatility due to deferred tax adjustments
⚙️ Fixed vs Variable Cost Behavior Analysis
This analysis classifies costs by their behavior relative to revenue changes. A truly "variable" cost should move proportionally with revenue; a "fixed" cost stays constant regardless of volume. Hospital businesses typically have high operating leverage — large fixed cost base means small volume changes produce outsized profit swings. The FY21 COVID crash (revenue ↓20%) vs FY22 recovery (revenue ↑48%) provides a natural experiment.
Cost Elasticity to Revenue (FY18–FY25)
Revenue CAGR = 8.6%. Red = cost growing faster than revenue
Operating Leverage Effect
Revenue vs EBITDA YoY% — measures profit sensitivity to volume changes
Cost Behavior Classification
Based on correlation with revenue and CAGR relative to revenue CAGR
People Cost (Payroll + Doctor) as % of Revenue
The single biggest cost lever — 36.7% of revenue in FY25
Material Cost Ratio — Medicines & Consumables
Remarkably stable at 27–29% — well managed procurement
🏛️ DuPont Analysis — Decomposing Return on Equity
ROE = Net Margin × Asset Turnover × Equity Multiplier. This decomposition reveals whether returns are driven by profitability, efficiency, or leverage. For LHRC, the hospital is almost entirely equity-funded (multiplier ~1.27x), so ROE is principally a function of margins and asset utilization.
ROE FY25
9.5%
= 9.6% × 0.78x × 1.27x
ROA FY25
7.5%
PAT/Avg Assets
ROCE FY25
12.6%
EBIT / Capital Employed
Asset Turnover
0.78x
Revenue / Avg Total Assets
ROE, ROA & ROCE Trend
Return metrics across the cycle
DuPont Decomposition
Net Margin % × Asset Turnover × Equity Multiplier
DuPont Table — Full Decomposition
CFO FY25
₹68.3 Cr
Best ever · ↑55% YoY
FCF FY25
₹45.6 Cr
CFO – Capex
Total Debt
₹0 Cr
Debt-free since FY24!
Cash + Bank
₹106 Cr
Cash ₹44Cr + FD ₹62Cr
Dividend FY25
₹17 Cr
43.5% payout ratio
✅ Fortress Balance Sheet — Cash Machine Status Achieved
LHRC is now debt-free with ₹106 Cr in cash/bank balances. The hospital generates ₹45–68 Cr of annual operating cash flow. After capex and dividends, it still accumulates cash. The strategic question is no longer "can we survive" but "what's the best use of excess cash — expansion, acquisitions, or higher shareholder returns?"
Cash Flow from Operations, Investing & Financing
CFO consistently positive — investing for growth
Free Cash Flow & Dividend Coverage
FCF = CFO – Capex · How much is left after reinvestment
Debt Reduction Journey
From ₹42 Cr total debt (FY19) to zero
Cash & Bank Balance Accumulation
Liquid assets on balance sheet
Total Assets
₹533 Cr
↑5% YoY
Equity
₹422 Cr
79.2% of assets
Net Fixed Assets
₹347 Cr
65.1% of assets — asset heavy
Working Capital Days
—
Trade Rec – Trade Pay cycle
Asset Composition Over Time
PPE dominates — typical for hospital businesses
Working Capital Metrics
Receivable days & inventory days trend
Balance Sheet Summary (₹ Lakhs)
🎯 Board-Level Strategic Summary — FY25
The hospital has 3 strengths (debt-free, strong cash generation, revenue scale) and 3 urgent concerns (margin compression, revenue plateau, rising cost intensity). The next 12–18 months will determine if LHRC can return to 22%+ EBITDA margins or if the FY23 peak was an anomaly driven by post-COVID tailwinds.
HEADLINE METRICS — THE BIG PICTURE
STRATEGIC SCORECARD
THE 5 THINGS THE CEO SHOULD DO NOW
🔴 Immediate Actions (0–6 months)
1. Payroll Audit: Payroll has risen from 15.2% to 19.5% of revenue — a ₹17 Cr annual drag. Commission a headcount-to-productivity analysis across all departments.
2. Revenue Recovery Plan: FY24 revenue actually declined 5.5%. Need a department-wise revenue acceleration playbook — especially for the top 5 departments that generate 70%+ of revenue.
3. Receivables Tightening: Trade receivables jumped from ₹27 Cr to ₹34 Cr — receivable days creeping up. Implement stricter collection protocols for TPA/insurance.
🟡 Medium-Term Priorities (6–18 months)
4. Capital Allocation Strategy: With ₹106 Cr cash and zero debt, the balance sheet is underleveraged. Explore: (a) capacity expansion (new beds/specialties), (b) acquisition of a smaller hospital/clinic chain, or (c) special dividend if no growth opportunities merit investment.
5. Marketing ROI Analysis: Marketing spend went from ₹1.2 Cr to ₹7 Cr (6x increase), but revenue growth has stalled. Need to measure patient acquisition cost and channel effectiveness before further increases.
HISTORICAL PERFORMANCE MAP
Revenue vs EBITDA Margin Scatter
Each dot = one fiscal year · Size = PAT
Year-over-Year Performance Heatmap